Infliximab News and Research

RSS

Infliximab is a monoclonal antibody that blocks the action of a cytokine called tumor necrosis factor alfa. It is being studied in the treatment and prevention of weight loss and loss of appetite in patients with advanced cancer. It belongs to the family of drugs called monoclonal antibodies.

Immune modulator drugs improved clinical status, reduced deaths among patients hospitalized with COVID-19

A large randomized, placebo-controlled clinical trial led by the National Institutes of Health shows that treating adults hospitalized with COVID-19 with infliximab or abatacept - drugs widely used to treat certain autoimmune diseases - did not significantly shorten time to recovery but did substantially improve clinical status and reduce deaths.

2 Jun 2022

Two cases of MIS-C after laboratory-confirmed SARS-CoV-2 breakthrough infections in fully vaccinated adolescent patients

Researchers investigated whether COVID-19 vaccination effectively protected adolescents in the United States from multisystem inflammatory syndrome (MIS).

2 Jun 2022

Gut microbiota linked to immunocompromised people's variable response to SARS-CoV-2 vaccination

In a recent study posted to the Research Square* preprint server, researchers assessed whether disturbances in the gut microbiota weaken the serological response to the coronavirus disease 2019 (COVID-19) vaccine in inflammatory bowel disease (IBD) patients.

25 May 2022

New insight into lymphoid cell maturity could pave the way for more effective IBD treatments

A research group at Karolinska Institutet in Sweden has analyzed how certain immune cells known as innate lymphoid cells (ILCs) develop into mature cells that play a part in inflammatory bowel disease (IBD).

15 Apr 2022

Heart complications uncommon for children and young adults after SARS-CoV-2 infection

Heart complications are uncommon, yet treatable for children and young adults after COVID-19 disease or SARS-CoV-2 infection, according to a new scientific statement from the American Heart Association that details what has been learned about how to treat, manage and even prevent cardiovascular complications from the SARS-CoV-2 virus in youth.

12 Apr 2022

Study explores COVID-19 vaccine effectiveness in ankylosing spondylitis patients

Researchers estimated the immunogenicity of SARS-CoV-2 vaccination in a Belgian cohort of patients with ankylosing spondylitis.

7 Mar 2022

Trial identifies a drug that may benefit some patients hospitalized with COVID-19 pneumonia

A proof-of-concept trial led by the Universities of Birmingham and University Hospitals Birmingham NHS Foundation Trust has identified a drug that may offer benefit some patients hospitalized with COVID-19 pneumonia.

18 Dec 2021

People taking immunosuppressant produce weaker, shorter-lived antibodies after COVID-19 vaccination

People who received two doses of the Pfizer COVID-19 vaccine while on TNF inhibitors -; a class of immunosuppressants used to treat rheumatoid arthritis and other autoimmune conditions -; generated less powerful and shorter-lived antibodies against the virus that causes COVID-19 than healthy people and those on other kinds of immunosuppressants, according to a study by researchers at Washington University School of Medicine in St. Louis.

21 Nov 2021

Immune response elicited by SARS-CoV-2 vaccines in infliximab and vedolizumab-treated patients with IBD

A recent study evaluates the immune responses elicited by COVID-19 vaccines in infliximab- or vedolizumab-treated IBD patients.

15 Nov 2021

Studies test intravenous immunoglobulin for treatment of Kawasaki disease and MIS-C

Kawasaki disease (KD) is rare, with fewer than 6,000 diagnosed cases per year in the United States. It is most common in infants and young children and causes inflammation in the walls of some blood vessels in the body.

27 Oct 2021

Can targeting autophagy become a new approach to COVID-19 treatment?

In a recent review, the author discusses autophagy as a contributing mechanism of selected drugs that are currently being evaluated to treat COVID‐19.

25 Oct 2021

Real-world data sheds new light on biologic treatment and vaccine hesitancy in psoriasis patients

Real-world data looking at biologic treatment and vaccine hesitancy in psoriasis patients is being presented today at EADV’s 30th Congress.

1 Oct 2021

Dual therapy improves cardiac outcomes in pediatric patients suffering from MIS-C

A recent study by a multidisciplinary team of cardiologists and infectious disease specialists at Children's Hospital Colorado (Children's Colorado) found that pediatric patients suffering from Multisystem Inflammatory Syndrome (MIS-C) who received initial, intensified therapy consisting of intravenous immunoglobulin (IVIG) plus Infliximab had improved cardiac outcomes versus those who received IVIG alone.

30 Sep 2021

Humoral and cellular response to COVID-19 vaccines in patients with IBD

A new study published in the preprint server medRxiv* aimed to evaluate the humoral and cellular response to COVID-19 vaccine in patients with IBD undergoing biologic or immunomodulatory therapy.

17 Sep 2021

Commonly-prescribed drug for IBD blunts COVID-19 vaccine response

People who take a commonly-prescribed drug for inflammatory bowel disease (IBD) should not assume they are protected after a first dose of COVID-19 vaccine, after a large-scale study found many had poor antibody responses.

26 Apr 2021

Infliximab may hinder the effectiveness of some COVID-19 vaccines

A new study reports reduced vaccine efficacy following the use of a single COVID-19 vaccine dose in people who are on the immunosuppressive monoclonal antibody Infliximab.

31 Mar 2021

Researchers launch clinical trial to assess therapeutic drug monitoring for patients with inflammatory diseases

New research presented at ACR Convergence, the American College Rheumatology's annual meeting, showed that patients with rheumatic diseases whose infliximab treatment was individually assessed and adjusted with a new strategy called therapeutic drug monitoring did not achieve remission at higher rates compared to those who received standard care.

8 Nov 2020

Infliximab News and Research

Further Reading